• Hereditary angioedema

Berinert Generic Name & Formulations

General Description

C1 esterase inhibitor (human) 500 IU; per vial; freeze-dried pwd for IV inj after reconstitution; preservative-free.

Pharmacological Class

C1 inhibitor.

How Supplied

Single-use vial—1 (w. supplies)


Generic Availability


Berinert Indications


Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.

Limitations of Use

Safety and efficacy for prophylactic therapy have not been established.

Berinert Dosage and Administration

Adults and Children

Give 20 IU/kg by slow IV inj at a rate of approx. 4mL/min. Do not administer doses <20 IU/kg.

Berinert Contraindications

Not Applicable

Berinert Boxed Warnings

Not Applicable

Berinert Warnings/Precautions


Discontinue immediately if hypersensitivity reactions are suspected. Have epinephrine inj available. Monitor patients with known risk factors for thromboembolic events (eg, indwelling venous catheter/access device, history of thrombosis, atherosclerosis, morbid obesity, immobility). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.

Berinert Pharmacokinetics

See Literature

Berinert Interactions


Risk of thrombotic events with concomitant oral contraceptives or certain androgens.

Berinert Adverse Reactions

Adverse Reactions

Dysgeusia, increased severity of pain; hypersensitivity reactions, thromboembolic events.

Berinert Clinical Trials

See Literature

Berinert Note


To report infections that may have been transmitted by Berinert, call the CSL Behring Pharmacovigilance Department at (866) 915-6958.

Berinert Patient Counseling

See Literature